Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

TABRECTA: metastatic Non-small cell lung cancer with MET stated without a specific alteration

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1 INDICATIONS AND USAGE TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

Broader topic: Non-Small Cell Lung Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    MET
    alteration
    stated without a specific alteration
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for TABRECTA (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1 INDICATIONS AND USAGE TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.

    Study evidence for this setting

    4 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT00585195 · Source cited / selected · Scope: unclear

    A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

    6 outcome links · 21 safety-group records · 0 quality-of-life measures

    →

    NCT01822496 · Source cited / selected · Scope: unclear

    Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

    6 outcome links · 4 safety-group records · 0 quality-of-life measures

    →

    NCT02414139 · Source cited / selected · Scope: unclear

    Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

    6 outcome links · 26 safety-group records · 0 quality-of-life measures

    →

    NCT02864992 · Source cited / selected · Scope: unclear

    Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

    6 outcome links · 1 safety-group records · 3 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice